What’s next for GLP-1 weight loss drugs?

Novo Nordisk's Wegovy and Eli Lilly's Zepbound, established GLP-1 weight loss drugs, face increasing competition from other pharmaceutical companies. Pfizer and Amgen are developing similar medications to enter the lucrative market. Novo Nordisk and Eli Lilly are also working on new developments to maintain their leading positions in the weight loss drug sector. This competitive landscape is driving innovation and strategic moves within the pharmaceutical industry as companies vie for market share in the rapidly growing GLP-1 drug category. The popularity of these drugs has spurred significant investment and research efforts across multiple major pharmaceutical players aiming to replicate or improve upon the success of existing treatments.